Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model

被引：1

作者：

Goshima, Tsubasa ^{[1
,2
,3
]}

Ieguchi, Katsuaki ^{[1
,4
]}

Onishi, Nobuyuki ^{[1
,4
]}

Shimizu, Takashi ^{[1
,4
]}

Takayanagi, Daisuke ^{[1
,2
,4
]}

Watanabe, Makoto ^{[1
,4
,5
,6
]}

Fujimoto, Yuki ^{[1
,2
,4
]}

Ohkuma, Ryotaro ^{[2
]}

Suzuki, Risako ^{[2
]}

Tsurui, Toshiaki ^{[2
,5
,6
]}

Mura, Emiko ^{[2
]}

Iriguchi, Nana ^{[2
]}

Ishiguro, Tomoyuki ^{[2
]}

Shimokawa, Masahiro ^{[2
]}

Hirasawa, Yuya ^{[2
]}

Kubota, Yutaro ^{[2
]}

Ariizumi, Hirotsugu ^{[2
]}

Horiike, Atsushi ^{[2
]}

Yoshimura, Kiyoshi ^{[2
,4
,7
]}

Tsuji, Mayumi ^{[6
]}

Kiuchi, Yuji ^{[5
,6
]}

Kobayashi, Shinichi ^{[4
]}

Fujishiro, Jun ^{[3
]}

Hoffman, Robert M. ^{[8
,9
]}

Tsunoda, Takuya ^{[2
]}

Wada, Satoshi ^{[1
,2
,4
]}

机构：

[1] Showa Univ, Clin Res Inst Clin Pharmacol & Therapeut, Dept Clin Diagnost Oncol, Tokyo, Japan

[2] Showa Univ, Sch Med, Dept Med, Div Med Oncol, Tokyo, Japan

[3] Univ Tokyo Hosp, Dept Pediat Surg, Tokyo, Japan

[4] Showa Univ, Clin Res Inst Clin Pharmacol & Therapeut, Tokyo, Japan

[5] Showa Univ, Sch Med, Dept Pharmacol, Tokyo, Japan

[6] Showa Univ, Pharmacol Res Ctr, Tokyo, Japan

[7] Showa Univ, Clin Res Inst Clin Pharmacol & Therapeut, Dept Clin ImmunoOncol, Tokyo, Japan

[8] AntiCancer Inc, San Diego, CA USA

[9] Univ Calif San Diego, Dept Surg, San Diego, CA USA

来源：

ANTICANCER RESEARCH | 2024年 / 44卷 / 01期

关键词：

Immune checkpoint inhibitor; non-classical monocyte; flow cytometry; overall survival; MICROSATELLITE INSTABILITY;

D O I：

10.21873/anticanres.16784

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The response rate to immune checkpoint inhibitors (ICIs) is approximately 10%-30% and only in a few cancer types. In the present study, we determined whether non-classical monocytes (NCMs) could enhance ICI efficacy in colon cancer using a syngeneic mouse model. Materials and Methods: The MC38 C57BL/6 mouse colon cancer model was used. Cells collected from the bone marrow of C57BL/6 mice were cultured, and NCMs were fractionated by cell sorting and administered via the tail veins to the mice implanted with MC38 cells. The anti -mouse PD-L1 antibody was administered three times, and tumor volume and overall survival were observed. Results: More tumors were eradicated and more complete response occurred, after cotreatment with ICIs and NCMs than after treatment with ICIs alone. Moreover, no efficacy was observed when NCMs were administered alone. Conclusion: NCMs enhance ICI efficacy. The underlying mechanisms and clinical applications will be studied in the future.

引用

页码：23 / 29

页数：7

共 50 条

[31] Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer
Hosokawa, Shinobu
Ichihara, Eiki
Bessho, Akihiro
Harada, Daijiro
Inoue, Koji
Shibayama, Takuo
Kishino, Daizo
Harita, Shingo
Ochi, Nobuaki
Oda, Naohiro
Hara, Naofumi
Hotta, Katsuyuki
Maeda, Yoshinobu
Kiura, Katsuyuki
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (02) : 279 - 286
[32] Immune Checkpoint Inhibitors for Brain Metastases of Non-Small-Cell Lung Cancer
Ashinuma, H.
Shingyoji, M.
Iuchi, T.
Yoshida, Y.
Setoguchi, T.
Hasegawa, Y.
Sakaida, T.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2420 - S2420
[33] Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
Soh, Junichi
Hamada, Akira
Fujino, Toshio
Mitsudomi, Tetsuya
CANCERS, 2021, 13 (16)
[34] Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer
Bote, Helena
Mesas, Andres
Baena, Javier
Herrera, Mercedes
Paz-Ares, Luis
EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (03) : 289 - 300
[35] Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Ushio, Ryota
Murakami, Shuji
Saito, Haruhiro
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (07)
[36] A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer
Palma dos Reis, Ana Filipa
Simao, Diana
Odeny, Thomas
Rodrigues, Chiara
Fontes-Sousa, Mario
da Luz, Ricardo
Chowdry, Rajasree Pia
Welsh, Sarah J.
Paller, Channing
Barata, Pedro C.
KIDNEY CANCER, 2022, 6 (02) : 115 - 127
[37] Real-world evaluation of the efficacy of immune checkpoint inhibitors in the treatment of metastatic breast cancer
Qian, Xiaoyan
Tao, Yunxia
Chen, Haizhu
Li, Xin
Wang, Yaqin
Xu, Xiaoming
Li, Shuo
Chen, Haoyu
Cang, Shundong
Liu, Yang
ONCOLOGY LETTERS, 2025, 29 (01)
[38] Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients
He, Xin
Wei, Shan-Na
Qin, Wen-Wen
Geng, Nan
Li, Bin
Song, Shan
Wang, Ping
EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (12) : 1135 - 1142
[39] Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis
Li, Yan
Ma, Yiqi
Wu, Zijun
Zeng, Fanxin
Song, Bin
Zhang, Yanrong
Li, Jinxing
Lui, Su
Wu, Min
FRONTIERS IN IMMUNOLOGY, 2021, 12
[40] High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer
Tone, Mari
Izumo, Takehiro
Awano, Nobuyasu
Kuse, Naoyuki
Inomata, Minoru
Jo, Tatsunori
Yoshimura, Hanako
Minami, Jonsu
Takada, Kohei
Miyamoto, Shingo
Kunitoh, Hideo
THORACIC CANCER, 2019, 10 (10) : 2006 - 2012

← 1 2 3 4 5 →